Tricida, Inc. (TCDA) |
|
0.108 0 (0%)
|
01-23 16:00 |
|
Open: |
0.1156 |
Pre. Close: |
0.108 |
|
High:
|
0.116 |
Low:
|
0.0925 |
|
Volume:
|
31,125,310 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:48:26 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.22  One year: 0.3 |
| Support: |
Support1: 0.09 Support2: 0.07 |
| Resistance: |
Resistance1: 0.19 Resistance2: 0.25 |
| Pivot: |
0.15 |
| Moving Average: |
MA(5): 0.12 MA(20): 0.15
MA(100): 4.35 MA(250): 7.62 |
| MACD: |
MACD(12,26): -0.2  Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 4.4 %D(3): 3.5 |
| RSI: |
RSI(14): 24.4 |
| 52-week: |
High: 13.85 Low: 0.09 |
| Average Vol(K): |
3-Month: 13,987 (K) 10-Days: 22,690 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TCDA ] has closed above bottom band by 0.5%. Bollinger Bands are 97.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 47 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.12 - 0.12 |
0.12 - 0.12 |
|
Low:
|
0.09 - 0.09 |
0.09 - 0.09 |
|
Close:
|
0.11 - 0.11 |
0.11 - 0.11 |
|
Company Description |
|
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. |
Headline News |
Fri, 27 Jan 2023
Team Creates New Method to Detect C Difficile in Fecal Samples - MD Magazine
Mon, 23 Jan 2023
Where Will Tricida Inc (TCDA) Stock Go Next After It Is Lower By 33.33% in a Week? - InvestorsObserver
Wed, 18 Jan 2023
Tricida Inc (TCDA) Stock: Do Analysts Think You Should Hold? - InvestorsObserver
Wed, 18 Jan 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Tue, 17 Jan 2023
Stocks Mostly Lower Tuesday as Investors Digest Mixed Earnings - InvestorsObserver
Fri, 13 Jan 2023
5 Cheapest Health Care Stocks You Should Think About - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
58 (M) |
| Shares Float |
51 (M) |
|
% Held by Insiders
|
8 (%) |
|
% Held by Institutions
|
64.7 (%) |
|
Shares Short
|
10,820 (K) |
|
Shares Short P.Month
|
14,640 (K) |
Stock Financials |
|
EPS
|
-2.88 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-2.45 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-60.2 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-2.14 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-109 (M) |
|
Levered Free Cash Flow
|
-66 (M) |
Stock Valuations |
|
PE Ratio
|
-0.04 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.05 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.06 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
